FRSM
20.08.2011, 00:27
β blockers are conventionally avoided in peripheral
arterial disease because of their effect on vasomotor
tone. But one such drug, nebivolol, has vasodilating,
endothelium dependent, nitric oxide releasing
properties that might actually benefit people
with peripheral arterial disease. A double blind
randomised trial of nebivolol and metoprolol in
patients with intermittent claudication and essential
hypertension over one year found a significant
improvement in absolute claudication distance
for both groups, and a significant increase in
initial claudication distance was reported in the
nebivolol group (Hypertension 2011;58:148-54).
arterial disease because of their effect on vasomotor
tone. But one such drug, nebivolol, has vasodilating,
endothelium dependent, nitric oxide releasing
properties that might actually benefit people
with peripheral arterial disease. A double blind
randomised trial of nebivolol and metoprolol in
patients with intermittent claudication and essential
hypertension over one year found a significant
improvement in absolute claudication distance
for both groups, and a significant increase in
initial claudication distance was reported in the
nebivolol group (Hypertension 2011;58:148-54).